Latigo Biotherapeutics, Inc. (LTGO) Balance Sheet
LTGO balance sheet, 2025
December 31, 2025 · U.S. dollars$75.5M assets = $307.2M liabilities + −$231.7M equity
Liabilities exceed assets: shareholders’ equity is negative (−$231.7M).
Both columns are drawn to the same scale: what LTGO owns equals what it owes plus shareholders’ equity. Hover a block for its value.
LTGO financial health
Descriptive bands, not a rating. Fiscal 2025.
LTGO balance sheet trends, 2024–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $22.9M2024 | $75.5M2025 | +230.3%/yr | |
| Total liabilities | $152.5M2024 | $307.2M2025 | +101.5%/yr | |
| Shareholders’ equity | −$129.6M2024 | −$231.7M2025 | — | |
| Cash & short-term investments | $17.9M2024 | $69.4M2025 | +287.5%/yr | |
| Working capital | $6.7M2024 | $55.4M2025 | +$48.7M | |
| Book value per share | −$2.152024 | −$3.852025 | — | |
| Current ratio | 1.472024 | 4.002025 | +2.54 | |
| Shares outstanding | 60.2M2024 | 60.2M2025 | 0.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
LTGO assets
LTGO liabilities and equity
LTGO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
LTGO balance sheet
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $69.4M | $17.9M |
| Cash & equivalents | $69.4M | $17.9M |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other current assets | $4.4M | $3.2M |
| Total current assets | $73.8M | $21.2M |
| Property, plant & equipment (net) | $1.1M | $1.4M |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $616,000 | $290,000 |
| Total assets | $75.5M | $22.9M |
| Liabilities | ||
| Accounts payable | $5.0M | $7.1M |
| Total current liabilities | $18.4M | $14.4M |
| Long-term debt | $0 | $0 |
| Lease obligations | $690,000 | $851,000 |
| Other long-term liabilities | $288.7M | $138.0M |
| Total liabilities | $307.2M | $152.5M |
| Shareholders' equity | ||
| Retained earnings (deficit) | −$243.1M | −$134.0M |
| Total shareholders' equity | −$231.7M | −$129.6M |
| Key figures | ||
| Working capital | $55.4M | $6.7M |
| Tangible book value | −$231.7M | −$129.6M |
| Book value per share | −$3.85 | −$2.15 |
| Shares outstanding | 60.2M | 60.2M |
| Current ratio | 4.00 | 1.47 |
| Quick ratio | 3.76 | 1.24 |
| Equity / assets | −306.8% | −566.8% |
| Jun '26 | Mar '26 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $55.0M | $42.2M |
| Cash & equivalents | $55.0M | $42.2M |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other current assets | $4.2M | $4.7M |
| Total current assets | $59.2M | $46.8M |
| Property, plant & equipment (net) | $1.8M | $900,000 |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $3.8M | $2.8M |
| Total assets | $64.8M | $50.6M |
| Liabilities | ||
| Accounts payable | $3.6M | $4.5M |
| Total current liabilities | $51.6M | $14.5M |
| Long-term debt | $0 | $0 |
| Lease obligations | $1.4M | $554,000 |
| Other long-term liabilities | $289.3M | $288.7M |
| Total liabilities | $340.8M | $303.2M |
| Shareholders' equity | ||
| Retained earnings (deficit) | −$291.9M | −$266.1M |
| Total shareholders' equity | −$276.1M | −$252.6M |
| Key figures | ||
| Working capital | $7.6M | $32.4M |
| Tangible book value | −$276.1M | −$252.6M |
| Book value per share | −$4.59 | −$4.20 |
| Shares outstanding | 60.2M | 60.2M |
| Current ratio | 1.15 | 3.23 |
| Quick ratio | 1.07 | 2.91 |
| Equity / assets | −426.3% | −499.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed —); data from EODHD.
LTGO financial position
At the end of fiscal 2025 (December 31, 2025), Latigo Biotherapeutics had total assets of $75.5 million (up 230.3% from a year earlier), total liabilities of $307.2 million and shareholders' equity of -$231.7 million. Its current ratio was 4.00. In the latest quarter (ended June 30, 2026) total assets were $64.8 million and equity -$276.1 million.
Related: LTGO income statement, LTGO cash flow statement, LTGO key metrics. See the LTGO stock overview for the latest quote and news.
LTGO balance sheet FAQ
What are Latigo Biotherapeutics's total assets?
Latigo Biotherapeutics reported total assets of $75.5 million at the end of fiscal 2025 (December 31, 2025), compared with $22.9 million a year earlier.
How much cash does Latigo Biotherapeutics have?
Latigo Biotherapeutics held $69.4 million in cash and short-term investments at the end of fiscal 2025.
What is Latigo Biotherapeutics's book value?
Latigo Biotherapeutics's shareholders' equity (book value) was -$231.7 million at the end of fiscal 2025, or −$3.85 per share.
What is Latigo Biotherapeutics's current ratio?
Latigo Biotherapeutics had current assets of $73.8 million and current liabilities of $18.4 million, a current ratio of 4.00 (it can cover its short-term obligations).